Market closedNon-fractional

X4 Pharmaceuticals/XFOR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About X4 Pharmaceuticals

X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Ticker

XFOR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Boston, United States

Employees

116

XFOR Metrics

BasicAdvanced
$92M
Market cap
-
P/E ratio
-$0.67
EPS
0.51
Beta
-
Dividend rate
$92M
0.51
3.71
3.465
5,515.637
5,625
-17.66%
-61.03%
-489.12%
88.96
-5.65
-1.013
-35.86%
-44.04%

What the Analysts think about XFOR

Analyst Ratings

Majority rating from 6 analysts.
Buy

XFOR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$52M
170.68%
Profit margin
0.00%
NaN%

XFOR Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 59.65%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.33
-$0.01
-$0.10
-$0.26
-
Expected
-$0.16
-$0.15
-$0.15
-$0.16
$0.01
Surprise
102.04%
-93.28%
-34.58%
59.65%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for X4 Pharmaceuticals stock?

X4 Pharmaceuticals (XFOR) has a market cap of $92M as of July 06, 2024.

What is the P/E ratio for X4 Pharmaceuticals stock?

The price to earnings (P/E) ratio for X4 Pharmaceuticals (XFOR) stock is 0 as of July 06, 2024.

Does X4 Pharmaceuticals stock pay dividends?

No, X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next X4 Pharmaceuticals dividend payment date?

X4 Pharmaceuticals (XFOR) stock does not pay dividends to its shareholders.

What is the beta indicator for X4 Pharmaceuticals?

X4 Pharmaceuticals (XFOR) has a beta rating of 0.51. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell X4 Pharmaceuticals stock

Buy or sell X4 Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing